Journal article
Hepatitis B screening to reduce the risk of viral reactivation in gynecologic oncology patients receiving chemotherapy at a regional tertiary cancer center: A quality improvement initiative.
Abstract
332
Background: In 2020, ASCO released a Provisional Clinical Opinion recommending universal hepatitis B virus (HBV) screening prior to systemic chemotherapy to reduce the risk of reactivation and associated morbidities. There is limited data for HBV prevalence and risk factors in gynecologic oncology. In gynecologic oncology patients at the Juravinski Cancer Centre, median baseline screening rate over 6 months was 0%. Our aim …
Authors
Mah SJ; Bellini J; Zhao L; Van Nguyen JM; Reade C; Jimenez W; Carlson V; Tyagi NJK; Bernard L; Pond GR
Journal
Journal of Clinical Oncology, Vol. 40, No. 28_suppl, pp. 332–332
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
October 1, 2022
DOI
10.1200/jco.2022.40.28_suppl.332
ISSN
0732-183X